abt-199 and Mastocytosis--Systemic

abt-199 has been researched along with Mastocytosis--Systemic* in 1 studies

Other Studies

1 other study(ies) available for abt-199 and Mastocytosis--Systemic

ArticleYear
Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia.
    European journal of haematology, 2023, Volume: 110, Issue:2

    Systemic mastocytosis (SM) results from clonal proliferation of neoplastic mast cells that infiltrate bone marrow and other organs. A major subset of patients with SM has a clonally related myeloid neoplasm and the SM itself (SM-AMN). We evaluated the efficacy of hypomethylating agent and venetoclax (HMA-VEN) to target both the myeloid neoplasm and mast cell infiltrate in a patient with SM associated with acute myeloid leukemia arising from myelodysplastic syndrome and illustrate complete elimination of bone marrow mast cells and complete remission of MDS/AML. This case illustrates the potent activity of HMA-VEN both against the AMN as well as the associated SM.

    Topics: Bone Marrow; Humans; Leukemia, Myeloid, Acute; Mast Cells; Mastocytosis, Systemic; Myelodysplastic Syndromes; Myeloproliferative Disorders

2023